{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Complete Response (CR) Converted Post Transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"CR Prior to Transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Progressive Disease (PD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Response defined by Physician's Global Assessment of Clinical Condition (PGA) where Complete Response (CR) is No evidence of disease; 100% improvement; Partial Response (PR), one of following: 1) Very significant clearance ( \\> 90% to \\< 100%); only traces of disease remains; 2) Significant improvement ( \\> 75% to \\< 90%); some evidence of disease remain; 3) Intermediate between slight and marked improvement; ( \\> 50% to \\< 75%); 4) Some improvement ( \\> 25% to \\< 50%); however, significant evidence of disease remains; Stable Disease (SD): Disease has not changed from baseline condition (+\\<25%); Progressive Disease (PD): Disease is worse than at baseline evaluation by \\> 25% or more. Response confirmed by a second assessment at least 4 weeks following it. Assessments at baseline, pre and post transplant (100 days) then till disease progression or year one.","groups":[{"description":"Fludarabine 25 mg/m\\^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m\\^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine \\& Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 \\& -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.","id":"OG000","title":"Fludarabine + Melphalan With PBPC"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Response assessed pre-transplant and 100 days post transplant with follow up at 1 year.","title":"Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA)","type":"PRIMARY","unitOfMeasure":"participants"}